Three of the four drugs showed a high incidence of hepatic impairment in the Japanese population (Table 2 ), and another drug, Eribulin mesilate also showed a trend toward a higher incidence of hepatic impairment in the Japanese population (7/81 subjects, 8.6%) than in non-Japanese populations (16/827 subjects, 1.9%) according to the review report [ 18 ].
← all excerpts
Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan.
1
—
—